{"id":"amlodipine-indapamide","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Fatigue"},{"rate":"2-5","effect":"Hypokalemia"},{"rate":"1-3","effect":"Hyperuricemia"},{"rate":"2-4","effect":"Flushing"}]},"_chembl":{"chemblId":"CHEMBL406","moleculeType":"Small molecule","molecularWeight":"365.84"},"_dailymed":{"setId":"a30ff81d-420b-40ea-83d8-670260a93fff","title":"WIDAPLIK (TELMISARTAN, AMLODIPINE AND INDAPAMIDE) TABLET [AZURITY PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that inhibits L-type calcium channels in vascular smooth muscle, causing vasodilation and reduced peripheral resistance. Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing blood volume and intracellular calcium in vascular smooth muscle. The combination provides synergistic antihypertensive effects through complementary mechanisms.","oneSentence":"Amlodipine relaxes blood vessels by blocking calcium channels, while indapamide reduces blood volume and sodium levels through diuretic action, together lowering blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:08.521Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Essential hypertension in patients requiring combination therapy"}]},"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT07240909","phase":"PHASE4","title":"Antihypertensive Drug Selection Based on Hemodynamic Phenotypes","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2026-01","conditions":"Hypertension","enrollment":240},{"nctId":"NCT07232966","phase":"PHASE3","title":"Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Yan Li","startDate":"2025-11-20","conditions":"Resistant Hypertension","enrollment":220},{"nctId":"NCT05103332","phase":"PHASE2","title":"Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)","status":"COMPLETED","sponsor":"Alnylam Pharmaceuticals","startDate":"2021-11-05","conditions":"Hypertension","enrollment":663},{"nctId":"NCT02699645","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-09-28","conditions":"Intracerebral Haemorrhage (ICH), Hypertension","enrollment":1671},{"nctId":"NCT03476616","phase":"PHASE4","title":"Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients","status":"COMPLETED","sponsor":"Hippocration General Hospital","startDate":"2018-09-01","conditions":"Hypertension, Obesity","enrollment":198},{"nctId":"NCT07064525","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension","status":"ENROLLING_BY_INVITATION","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-12-05","conditions":"Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure","enrollment":252},{"nctId":"NCT06259175","phase":"","title":"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2024-05-01","conditions":"Arterial Hypertension, HTN","enrollment":396},{"nctId":"NCT04518293","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-07-09","conditions":"Hypertension","enrollment":1385},{"nctId":"NCT04518306","phase":"PHASE3","title":"Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension","status":"COMPLETED","sponsor":"George Medicines PTY Limited","startDate":"2021-06-14","conditions":"Hypertension","enrollment":755},{"nctId":"NCT06012487","phase":"PHASE1","title":"Correlates and Control of Blood Pressure Variability","status":"NOT_YET_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2026-05-01","conditions":"Blood Pressure Variability","enrollment":10},{"nctId":"NCT06826872","phase":"PHASE2","title":"Efficacy and Safety of SPC1001 in Patients With Essential Hypertension","status":"RECRUITING","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2024-06-12","conditions":"Hypertension, Essential, Cardiovascular Diseases, Cardiology","enrollment":252},{"nctId":"NCT03640312","phase":"PHASE2","title":"Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-08-30","conditions":"Hypertension","enrollment":62},{"nctId":"NCT05683301","phase":"PHASE4","title":"Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India","status":"COMPLETED","sponsor":"Centre for Chronic Disease Control, India","startDate":"2022-08-30","conditions":"Primary Hypertension","enrollment":1981},{"nctId":"NCT05820880","phase":"PHASE3","title":"Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-05-06","conditions":"Hypertension","enrollment":532},{"nctId":"NCT05899920","phase":"NA","title":"Clinical One-stage Controlled Study of reSistant Arterial Hypertension for the desiGning of a personAlized Approach to Therapy","status":"RECRUITING","sponsor":"Ryazan State Medical University","startDate":"2022-03-11","conditions":"Resistant Arterial Hypertension","enrollment":190},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT06212648","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2022-03-25","conditions":"Hypertension, Essential Hypertension","enrollment":253},{"nctId":"NCT04036409","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-05","conditions":"Ischemic Stroke, Blood Pressure, Cognitive Impairment","enrollment":4369},{"nctId":"NCT02364089","phase":"NA","title":"Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-04-09","conditions":"Adrenal Incidentalomas","enrollment":78},{"nctId":"NCT05377203","phase":"PHASE4","title":"Low-dose Quadruple Combination Therapy in Patients With Hypertension","status":"COMPLETED","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2022-07-13","conditions":"Hypertension, Arterial Hypertension","enrollment":90},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT05470764","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-30","conditions":"Bioequivalence, Healthy Subjects","enrollment":52},{"nctId":"NCT05169021","phase":"PHASE4","title":"Folic Acid and Intensive Antihypertensive Therapy for Hypertension With CSVD","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-12-31","conditions":"Cerebral Small Vessel Diseases, Stroke","enrollment":15000},{"nctId":"NCT04455178","phase":"PHASE4","title":"The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-09-23","conditions":"Hypertension","enrollment":200},{"nctId":"NCT03722524","phase":"","title":"The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2018-10-01","conditions":"Arterial Hypertension","enrollment":1247},{"nctId":"NCT03783754","phase":"NA","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2018-08-09","conditions":"Stroke, Cerebral Small Vessel Diseases, Intracerebral Hemorrhage","enrollment":4},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03785067","phase":"PHASE3","title":"Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study","status":"TERMINATED","sponsor":"The George Institute","startDate":"2020-02-27","conditions":"Cognitive Decline, Intracerebral Hemorrhage, Dementia, Vascular","enrollment":1},{"nctId":"NCT03319823","phase":"PHASE4","title":"Treating Nocturnal Hypertension and Nocturia in African American Men","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-10-25","conditions":"High Blood Pressure","enrollment":""},{"nctId":"NCT04686643","phase":"PHASE3","title":"Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension","status":"UNKNOWN","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2021-02-01","conditions":"Hypertension","enrollment":306},{"nctId":"NCT03738761","phase":"PHASE4","title":"Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine","status":"COMPLETED","sponsor":"KRKA","startDate":"2018-02-13","conditions":"Hypertension","enrollment":471},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03626506","phase":"NA","title":"Spironolactone Versus Indapamide in Obese and Hypertensive Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2019-02-13","conditions":"Hypertension","enrollment":400},{"nctId":"NCT03747978","phase":"PHASE4","title":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-10-01","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":30},{"nctId":"NCT01996085","phase":"NA","title":"Non-invasive Haemodynamic Assessment in Hypertension","status":"COMPLETED","sponsor":"Military Institute od Medicine National Research Institute","startDate":"2013-01","conditions":"Arterial Hypertension","enrollment":144},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":"Hypertension, Hypertension Resistant to Conventional Therapy, Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent","enrollment":4},{"nctId":"NCT02655029","phase":"","title":"Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination","status":"COMPLETED","sponsor":"Servier Hellas Pharmaceuticals Ltd.","startDate":"2015-11-25","conditions":"Adherence to Medication Regime, Hypertensive Disease","enrollment":2285},{"nctId":"NCT01500590","phase":"PHASE4","title":"Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria","status":"UNKNOWN","sponsor":"Hospital Authority, Hong Kong","startDate":"2011-11","conditions":"Diabetes, Hypertensive Disease","enrollment":1400},{"nctId":"NCT02710552","phase":"PHASE4","title":"Low-dose Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":"Arterial Hypertension","enrollment":100},{"nctId":"NCT02710539","phase":"PHASE4","title":"Once-daily Fixed Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":"Arterial Hypertension","enrollment":100},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine + Indapamide","genericName":"Amlodipine + Indapamide","companyName":"Centre for Chronic Disease Control, India","companyId":"centre-for-chronic-disease-control-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine relaxes blood vessels by blocking calcium channels, while indapamide reduces blood volume and sodium levels through diuretic action, together lowering blood pressure. Used for Hypertension, Essential hypertension in patients requiring combination therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}